PRMT1

Across TCGA pan-cancer cohorts, PRMT1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRMT1 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PRMT1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRMT1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

KIRP, CESC, and ESCA are the cancer types where PRMT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.115	0.867	<.001	24	view →
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	18	view →
ESCA	OS	Median	All	0.022	0.701	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
STAD	DFS	Median	All	1.000	0.647	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRMT1–KIRP (DFS)

Open the KIRP breakdown →